Technical Analysis for PLX - Protalix BioTherapeutics, Inc.

Grade Last Price % Change Price Change
grade F 0.2 -3.38% -0.01
PLX closed down 3.38 percent on Friday, September 20, 2019, on 34 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical PLX trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Pocket Pivot Bullish Swing Setup -7.32%
Narrow Range Bar Range Contraction -7.32%
NR7 Range Contraction -7.32%
Inside Day Range Contraction -7.32%
20 DMA Resistance Bearish -7.11%
Fell Below 20 DMA Bearish -8.09%
1,2,3 Retracement Bearish Bearish Swing Setup -12.09%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -12.09%
Crossed Above 20 DMA Bullish -12.09%

Older signals for PLX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company's product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-105, a plant cell expressed pegylated recombinant acetylcholinesterase product candidate for biodefense and other indications; and an orally-administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant enzyme produced within carrot cells. Its product pipeline also comprises PRX-106 or pr-antiTNF, a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor and an antibody portion, which is being developed as a treatment of certain immune diseases, such as rheumatoid arthritis, Chrohn's disease, placque psoriasis, and other autoimmune disorders; and two additional undisclosed therapeutic proteins that are being evaluated in animal studies. It has a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. to develop and manufacture two proteins using its ProCellEx protein expression system. The company was founded in 1993 and is based in Carmiel, Israel.
Biotechnology Biopharmaceutical Life Sciences Biology Rheumatoid Arthritis Autoimmune Disorders Enzyme Replacement Therapy Fabry Disease Gaucher Disease Recombinant Dna Treatment Of Fabry Disease
Is PLX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 0.83
52 Week Low 0.1855
Average Volume 342,333
200-Day Moving Average 0.3925
50-Day Moving Average 0.2864
20-Day Moving Average 0.2186
10-Day Moving Average 0.2175
Average True Range 0.02
ADX 35.65
+DI 12.7736
-DI 23.0714
Chandelier Exit (Long, 3 ATRs ) 0.1993
Chandelier Exit (Short, 3 ATRs ) 0.2455
Upper Bollinger Band 0.2432
Lower Bollinger Band 0.194
Percent B (%b) 0.12
BandWidth 22.506862
MACD Line -0.0196
MACD Signal Line -0.0233
MACD Histogram 0.0037
Fundamentals Value
Market Cap 26.67 Million
Num Shares 133 Million
EPS -0.60
Price-to-Earnings (P/E) Ratio -0.33
Price-to-Sales 6.07
Price-to-Book 0.00
PEG Ratio -0.16
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.23
Resistance 3 (R3) 0.23 0.23 0.22
Resistance 2 (R2) 0.23 0.22 0.22 0.22
Resistance 1 (R1) 0.21 0.21 0.21 0.21 0.22
Pivot Point 0.21 0.21 0.20 0.20 0.21
Support 1 (S1) 0.19 0.20 0.19 0.19 0.18
Support 2 (S2) 0.19 0.19 0.19 0.18
Support 3 (S3) 0.17 0.19 0.18
Support 4 (S4) 0.17